Lenacapavir加两种广泛中和抗体Teropavimab和Zinlirvimab，用于对Teropavimab或Zinlirvimab高度敏感的HIV-1患者。

IF 5 2区医学 Q2 IMMUNOLOGY

Journal of Infectious Diseases Pub Date : 2025-04-03 DOI:10.1093/infdis/jiaf159

Joseph J Eron, Paul P Cook, Megha L Mehrotra, Hailin Huang, Marina Caskey, Gordon E Crofoot, Linda Gorgos, Laurie A VanderVeen, Yanan Zheng, Sean E Collins, Olayemi O Osiyemi, Cynthia Brinson, Edwin DeJesus

{"title":"Lenacapavir加两种广泛中和抗体Teropavimab和Zinlirvimab，用于对Teropavimab或Zinlirvimab高度敏感的HIV-1患者。","authors":"Joseph J Eron, Paul P Cook, Megha L Mehrotra, Hailin Huang, Marina Caskey, Gordon E Crofoot, Linda Gorgos, Laurie A VanderVeen, Yanan Zheng, Sean E Collins, Olayemi O Osiyemi, Cynthia Brinson, Edwin DeJesus","doi":"10.1093/infdis/jiaf159","DOIUrl":null,"url":null,"abstract":"Background: The combination of two broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only one of the two bNAbs.Methods: Pilot study within a proof-of-concept Phase 1b study (NCT04811040).Results: No serious treatment-emergent adverse events occurred and 8/10 participants remained virologically suppressed at Week 26.Conclusions: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment.","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.\",\"authors\":\"Joseph J Eron, Paul P Cook, Megha L Mehrotra, Hailin Huang, Marina Caskey, Gordon E Crofoot, Linda Gorgos, Laurie A VanderVeen, Yanan Zheng, Sean E Collins, Olayemi O Osiyemi, Cynthia Brinson, Edwin DeJesus\",\"doi\":\"10.1093/infdis/jiaf159\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The combination of two broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only one of the two bNAbs.Methods: Pilot study within a proof-of-concept Phase 1b study (NCT04811040).Results: No serious treatment-emergent adverse events occurred and 8/10 participants remained virologically suppressed at Week 26.Conclusions: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment.\",\"PeriodicalId\":50179,\"journal\":{\"name\":\"Journal of Infectious Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiaf159\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf159","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：特罗帕维单抗和津利维单抗这两种广谱中和抗体（bNAb）与囊膜抑制剂来那卡巴韦的组合是一种潜在的每年两次的HIV-1治疗方案。维持病毒学抑制的 bNAb 敏感性水平尚不清楚；因此，我们评估了符合严格病毒敏感性标准的参与者对两种 bNAb 中仅一种 bNAb 的使用情况：方法：概念验证 1b 期研究（NCT04811040）中的试验性研究：结果：没有发生严重的治疗突发不良事件，8/10的参与者在第26周时病毒仍被抑制：结论：对于这种联合疗法的未来研究，可能应该采用更具包容性的 bNAb 易感性标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.

Background: The combination of two broadly neutralizing antibodies (bNAbs), teropavimab and zinlirvimab, plus the capsid inhibitor lenacapavir, is a potential twice-yearly regimen for HIV-1 treatment. The level of bNAb susceptibility to maintain virologic suppression is unknown; therefore, we evaluated this combination in participants meeting stringent viral sensitivity criteria to only one of the two bNAbs.

Methods: Pilot study within a proof-of-concept Phase 1b study (NCT04811040).

Results: No serious treatment-emergent adverse events occurred and 8/10 participants remained virologically suppressed at Week 26.

Conclusions: More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Infectious Diseases 医学-传染病学

CiteScore

13.50

自引率

3.10%

发文量

449

审稿时长

2-4 weeks

期刊介绍： Published continuously since 1904, The Journal of Infectious Diseases (JID) is the premier global journal for original research on infectious diseases. The editors welcome Major Articles and Brief Reports describing research results on microbiology, immunology, epidemiology, and related disciplines, on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune responses. JID is an official publication of the Infectious Diseases Society of America.